Literature DB >> 32458788

Changing Susceptibility Pattern of Vibrio cholerae O1 Isolates to Commonly Used Antibiotics in the Largest Diarrheal Disease Hospital in Bangladesh during 2000-2018.

Irin Parvin1, K M Shahunja2, Soroar Hossain Khan1, Tahmina Alam1, Lubaba Shahrin1, Mst Mahmuda Ackhter1, Monira Sarmin1, Sampa Dash3, Muhammad Waliur Rahman1, Abu Sadat Mohammad Sayeem Bin Shahid1, Abu Syed Golam Faruque1, Tahmeed Ahmed1, Mohammod Jobayer Chisti1.   

Abstract

The efficacy of commonly used antibiotics for treating severe cholera has been compromised over time because of the reduced antibiotic susceptibility. This study aimed to describe the rate of detection of Vibrio cholerae O1 from fecal samples and antimicrobial susceptibility profiles of V. cholerae O1 serotypes to commonly used antibiotics. During January 2000-December 2018, V. cholerae O1 was detected in fecal samples of 7,472 patients. Vibrio cholerae O1 Inaba serotype was predominant, ranging from 60% to 86% during the period 2000-2006 except for 2003 and 2005 when the Ogawa serotype was predominant. Later on, the Ogawa serotype became predominant from 2007 to 2015, fluctuating between 52% and 100%. However, in 2016 and 2017, isolation rates declined to 2% and 1%, respectively, but surged again to 75% in 2018. Nearly 100% of V. cholerae O1 strains were sensitive to tetracycline during 2000-2004. Thereafter, a declining trend of sensitivity was observed to be continued and dropped down to < 6% during 2012-2017 and again increased to 76% in 2018. Susceptibility to azithromycin and ciprofloxacin was nearly 100%, and susceptibility to cotrimoxazole and furazolidone was 01% throughout the study period. We also found the emergence of resistance to erythromycin in 2005 and sensitivity to cotrimoxazole in 2018. Thus, the rapid decline of the sensitivity of V. cholerae O1 to tetracycline and a reversed peak after 6 years need continued monitoring and reporting.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32458788      PMCID: PMC7410410          DOI: 10.4269/ajtmh.20-0058

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  35 in total

1.  TETRACYCLINE IN THE TREATMENT OF CHOLERA.

Authors:  W B GREENOUGH; R S GORDON; I S ROSENBERG; B I DAVIES; A S BENENSON
Journal:  Lancet       Date:  1964-02-15       Impact factor: 79.321

Review 2.  A review of antibiotic use in food animals: perspective, policy, and potential.

Authors:  Timothy F Landers; Bevin Cohen; Thomas E Wittum; Elaine L Larson
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

Review 3.  Update on the antibiotic resistance crisis.

Authors:  Gian Maria Rossolini; Fabio Arena; Patrizia Pecile; Simona Pollini
Journal:  Curr Opin Pharmacol       Date:  2014-09-23       Impact factor: 5.547

4.  Optimal antibiotic therapy in cholera.

Authors:  C K Wallace; P N Anderson; T C Brown; S R Khanra; G W Lewis; N F Pierce; S N Sanyal; G V Segre; R H Waldman
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

5.  The know-do gap in quality of health care for childhood diarrhea and pneumonia in rural India.

Authors:  Manoj Mohanan; Marcos Vera-Hernández; Veena Das; Soledad Giardili; Jeremy D Goldhaber-Fiebert; Tracy L Rabin; Sunil S Raj; Jeremy I Schwartz; Aparna Seth
Journal:  JAMA Pediatr       Date:  2015-04       Impact factor: 16.193

6.  Clinical features, antimicrobial susceptibility and toxin production in Vibrio cholerae O139 infection: comparison with V. cholerae O1 infection.

Authors:  U Dhar; M L Bennish; W A Khan; C Seas; E Huq Khan; M J Albert; M Abdus Salam
Journal:  Trans R Soc Trop Med Hyg       Date:  1996 Jul-Aug       Impact factor: 2.184

7.  Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139.

Authors:  W A Khan; M L Bennish; C Seas; E H Khan; A Ronan; U Dhar; W Busch; M A Salam
Journal:  Lancet       Date:  1996-08-03       Impact factor: 79.321

8.  Surveillance of patients attending a diarrhoeal disease hospital in Bangladesh.

Authors:  B J Stoll; R I Glass; M I Huq; M U Khan; J E Holt; H Banu
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-23

9.  Antimicrobial resistance of Vibrio cholerae O1 serotype Ogawa isolated in Manhiça District Hospital, southern Mozambique.

Authors:  Inácio Mandomando; Mateu Espasa; Xavier Vallès; Jahit Sacarlal; Betuel Sigaúque; Joaquim Ruiz; Pedro Alonso
Journal:  J Antimicrob Chemother       Date:  2007-07-11       Impact factor: 5.790

10.  Global Cholera Epidemiology: Opportunities to Reduce the Burden of Cholera by 2030.

Authors:  Dominique Legros
Journal:  J Infect Dis       Date:  2018-10-15       Impact factor: 5.226

View more
  5 in total

1.  Multidrug-resistant enteric pathogens in older children and adults with diarrhea in Bangladesh: epidemiology and risk factors.

Authors:  Stephanie C Garbern; Tzu-Chun Chu; Monique Gainey; Samika S Kanekar; Sabiha Nasrin; Kexin Qu; Meagan A Barry; Eric J Nelson; Daniel T Leung; Christopher H Schmid; Nur H Alam; Adam C Levine
Journal:  Trop Med Health       Date:  2021-05-10

2.  Cholera outbreak in Forcibly Displaced Myanmar National (FDMN) from a small population segment in Cox's Bazar, Bangladesh, 2019.

Authors:  Abu S G Faruque; Azharul Islam Khan; Baitun Nahar; S M Rafiqul Islam; M Nasif Hossain; Syed Asif Abdullah; Soroar Hossain Khan; Md Sabbir Hossain; Feroz Hayat Khan; Mukeshkumar Prajapati; Yulia Widiati; A S M Mainul Hasan; Minjoon Kim; Jennie Musto; Maya Vandenent; John David Clemens; Tahmeed Ahmed
Journal:  PLoS Negl Trop Dis       Date:  2021-09-22

3.  Water, Sanitation, and Hygiene (WASH) Practices and Outreach Services in Settlements for Rohingya Population in Cox's Bazar, Bangladesh, 2018-2021.

Authors:  Asg Faruque; Baharul Alam; Baitun Nahar; Irin Parvin; Ashok Kumar Barman; Soroar Hossain Khan; M Nasif Hossain; Yulia Widiati; Asm Mainul Hasan; Minjoon Kim; Martin Worth; Maya Vandenent; Tahmeed Ahmed
Journal:  Int J Environ Res Public Health       Date:  2022-08-05       Impact factor: 4.614

Review 4.  Foodborne Pathogenic Vibrios: Antimicrobial Resistance.

Authors:  Dipanjan Dutta; Anupam Kaushik; Dhirendra Kumar; Satyabrata Bag
Journal:  Front Microbiol       Date:  2021-06-30       Impact factor: 5.640

Review 5.  Marine Actinomycetes, New Sources of Biotechnological Products.

Authors:  Sveta V Jagannathan; Erika M Manemann; Sarah E Rowe; Maiya C Callender; William Soto
Journal:  Mar Drugs       Date:  2021-06-25       Impact factor: 5.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.